Case Report
Prolonged Disease Course of COVID-19 in a Patient with CTLA-4 Haploinsufficiency
Table 2
SARS-CoV-2 PCR test results, anti-SARS-CoV-2 antibody levels, and convalescent plasma infusions.
| Days after start of first symptoms of COVID-19 | Protective antibody level | Antibody level (A/CO) | SARS-CoV-2 PCR | Ct-value | Sample |
| 7 | | | Positive | 24.6 | Oropharynx | 20 | | | Positive | 30.8 | Oropharynx | 25 | Negative | 0.020 | | | | 32 | | | Negative | NA | Bronchial washing | 33 | | | Positive | NA | Nasopharynx | 49 | | | Positive | NA | Nasopharynx | 61 | | | Positive | 29.7 | Sputum | 83 | | | Positive | 23.8 | Oropharynx | 88 | Negative | 0.024 | | | | 89 | | First transfusion of convalescent plasma | 89 | Positive | 4.830 | | | | 91 | | | Positive | NA | Oropharynx | 94 | | | Positive | 32.4 | Oropharynx | 96 | Negative | 0.527 | | | | 98 | Negative | 0.381 | | | | 101 | | | Positive | 28.1 | Oropharynx | 103 | | Second transfusion of convalescent plasma | 110 | Positive | 9.083 | Positive | 27.6 | Oropharynx | 116 | Positive | 10.203 | Positive | 38.9 | Oropharynx | 119 | | Third transfusion of convalescent plasma | 123 | Positive | 7.437 | Negative | NA | Oropharynx | 126 | | | Positive | 28.9 | Oropharynx | 130 | | | Negative | NA | Oropharynx | 131 | Positive | 4.523 | | | | 133 | | Fourth transfusion of convalescent plasma | 136 | | | Positive | NA | Oropharynx | 137 | Positive | 13.935 | Positive | 36.8 | Oropharynx | 143 | Positive | 12.567 | | | | 144 | | | Negative | NA | Oropharynx | 146 | | | Negative | NA | Oropharynx | 146 | | Fifth transfusion of convalescent plasma | 153 | | | Negative | NA | Oropharynx | 165 | Positive | >14 | Negative | NA | Oropharynx | 165 | | Sixth transfusion of convalescent plasma | 181 | Positive | >14 | Negative | NA | Oropharynx | 196 | | | Negative | NA | Oropharynx | 207 | Positive | 10.602 | | | | 236 | Positive | 4.050 | Negative | NA | Oropharynx | 275 | | | Negative | NA | Oropharynx | 291 | | First SARS-CoV-2 vaccine | 300 | Negative | <3.80 (IgG (AU/mL)) | | | | 319 | | Second SARS-CoV-2 vaccine | 384 | Negative | <1.85 (IgG (AU/mL)) | | | | 414 | | | Negative | NA | Oropharynx | 417 | Negative | <1.85 (IgG (AU/mL)) | | | | 553 | | | Negative | NA | Sputum |
|
|
Reference numbers for antibody levels are >1.1 A/CO and >13 AU/mL. Ct = cycle threshold. NA = not available.
|